---
title: "Weekly Recap | CHINARES PHARMA -5.79%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305530074.md"
description: "CHINARES PHARMA fell 5.79% this week to close at HK$4.395, compared with a 3.32% drop for the Hang Seng Index, trailing the benchmark by about 2.47 percentage points. The stock traded lower across all four sessions: it opened Monday at HK$4.665, slipped to HK$4.540 on Tuesday and finished the week at its low of HK$4.395 on Thursday, a steady downward drift. Weekly amplitude was 6.22%, while average daily volume of 6.0m shares sat 21."
datetime: "2026-11-14T05:30:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305530074.md)
  - [en](https://longbridge.com/en/news/305530074.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305530074.md)
generator: "portal-rs"
---

# Weekly Recap | CHINARES PHARMA -5.79%, consensus target above spot

## The Week

CHINARES PHARMA (3320.HK) fell 5.79% this week to close at HK$4.395, compared with a 3.32% drop for the Hang Seng Index, trailing the benchmark by about 2.47 percentage points. The stock traded lower across all four sessions: it opened Monday at HK$4.665, slipped to HK$4.540 on Tuesday and finished the week at its low of HK$4.395 on Thursday, a steady downward drift. Weekly amplitude was 6.22%, while average daily volume of 6.0m shares sat 21.4% below its 60-day median, leaving a quiet tape with no company-specific catalyst.\\n\\n## Analyst Ratings\\n\\nAmong 11 brokers covering the stock, 6 rate it buy, 4 rate it overweight and 1 hold, with no underweight or sell calls; the consensus rating is buy. The consensus target price of HK$6.489 sits about 47.6% above the spot price, with the highest target at HK$7.520 and the lowest at HK$5.640, suggesting moderate dispersion. Within the 29-name pharmaceutical sector coverage, it ranks fifth by number of ratings.\\n\\n## The Week Ahead\\n\\nHong Kong releases its unemployment rate on 17 November (previous 3.9%) and the composite CPI on 20 November (previous 1.9%). On the corporate side, CHINARES PHARMA reports fiscal Q3 results after market close on 24 November, putting revenue and profit trends in focus. With the stock now below its 20-day moving average, next week’s volume recovery is another thing to watch.\\n\\n*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [China Resources Pharmaceutical Unit Secures Approval for RMB 10 Billion Corporate Bond Issuance](https://longbridge.com/en/news/305661943.md)
- [China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion](https://longbridge.com/en/news/303715107.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)
- [The Tesla Cybercab Is Now Available In Dallas](https://longbridge.com/en/news/306159915.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**